Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	236.79M
Revenue (ttm)	122.12M
Net Income (ttm)	-60.16M
Shares Out	27.15M
EPS (ttm)	-2.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,177,085
Open	8.14
Previous Close	8.29
Day's Range	7.93 - 8.78
52-Week Range	7.93 - 24.17
Beta	2.07
Analysts	Buy
Price Target	35.25 (+304.24%)
Earnings Date	Nov 10, 2025

About ARCT

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOS...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 176
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Financial Performance

In 2024, ARCT's revenue was $152.31 million, a decrease of -8.69% compared to the previous year's $166.80 million. Losses were -$80.94 million, 172.3% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price target is $35.25, which is an increase of 304.24% from the latest price.

Price Target

$35.25

(304.24% upside)

Analyst Consensus: Buy